IDEXX Laboratories (IDXX) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of IDEXX Laboratories (NASDAQ: IDXX) recently:

• 8/11/2026 – IDEXX Laboratories had its price target lowered by Barclays PLC from $800.00 to $710.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – IDEXX Laboratories had its price target raised by Citigroup Inc. from $650.00 to $670.00. They now have a “neutral” rating on the stock.
• 8/5/2026 – IDEXX Laboratories had its price target raised by UBS Group AG from $620.00 to $670.00. They now have a “neutral” rating on the stock.
• 7/29/2026 – IDEXX Laboratories was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 7/27/2026 – IDEXX Laboratories had its price target lowered by UBS Group AG from $640.00 to $620.00. They now have a “neutral” rating on the stock.
• 7/14/2026 – IDEXX Laboratories was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 7/12/2026 – IDEXX Laboratories was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/25/2026 – IDEXX Laboratories was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.